Retrospective analysis shows improved outcomes in AML patients treated with venetoclax plus azacitidine, suggesting its efficacy as maintenance therapy.
Key Points
To evaluate long-term outcomes of venetoclax plus azacitidine treatment in patients with acute myeloid leukemia.
Retrospective analysis of 79 patients with naïve AML treated with VEN + AZA for at least 6 cycles.
Conducted across five hematology units in China from September 2021 to October 2024.
Median age was 67 years, with median treatment cycles of 9.
CR/CRi rate was 70.9%, with higher rates in patients with NPM1 (80.9%) and IDH2 (80.0%) mutations.
Median overall survival was 33.5 months, with 14 months median follow-up and 25.4 months median duration of response.
Patients over 65 had inferior OS (26.1 months) compared to younger patients, while lower VEN doses led to superior OS (P=0.032).